iRadimed (NASDAQ:IRMD) Releases Earnings Results, Meets Expectations

iRadimed (NASDAQ:IRMD) issued its quarterly earnings data on Friday. The medical equipment provider reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55, FiscalAI reports. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.

Here are the key takeaways from iRadimed’s conference call:

• Record third-quarter results included revenue of $24.2 million, up 14% year over year and 18% sequentially, while GAAP EPS rose to $0.51 from $0.43 a year ago.
• The 3870 MR IV pump launch is gaining traction, with more than 300 systems shipped in Q3, record pump and monitor bookings, and a growing backlog. Management estimates an opportunity of more than 10,000 replacement channels, with the new pump carrying an approximately 23%-25% higher ASP than the older model.
• The company reduced its 2026 revenue outlook to $91.7 million-$93.2 million from $91 million-$96 million and lowered its GAAP EPS range to $1.90-$1.94 from $1.90-$2.05, citing the need to moderate production ramping to protect quality.
• Manufacturing efficiencies lifted gross margin to 76% sequentially, and management expects further improvement in Q4 and potentially a return to 77%-78% or higher in 2027. Management also projected double-digit, potentially upper-teens, revenue growth in 2027 and ended the quarter with $63.3 million in cash while declaring a $0.20 quarterly dividend.

iRadimed Trading Down 10.4%

Shares of IRMD traded down $8.93 during trading hours on Friday, reaching $76.81. 167,104 shares of the company’s stock traded hands, compared to its average volume of 111,528. The firm’s 50 day simple moving average is $85.86 and its 200-day simple moving average is $92.79. The stock has a market cap of $982.23 million, a PE ratio of 42.91 and a beta of 0.91. iRadimed has a 12 month low of $76.35 and a 12 month high of $107.90.

Analysts Set New Price Targets

Several equities analysts have weighed in on IRMD shares. Needham & Company LLC started coverage on iRadimed in a report on Tuesday, September 22nd. They issued a “hold” rating for the company. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Insider Buying and Selling

In related news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the transaction, the director directly owned 19,581 shares of the company’s stock, valued at $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 34.60% of the stock is owned by insiders.

About iRadimed

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.